Kimberly Perez

23PUBLICATIONS
250CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer diagnosisCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 25, 2026
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.

|Feb 13, 2026
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun

|Nov 20, 2025
Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors.

Kimberly J Perez, Nora Horick, Joanna Baginksa

|Sep 10, 2025
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.

Jennifer J Knox, Grainne O'Kane, Daniel King

|Sep 02, 2025
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

Rishi Surana, Micaela Morgado, Ashwin Somasundaram

|May 09, 2025
Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.

Kimberly Perez, Jaydira Del Rivero, Erin B Kennedy

Pageof 4

Frequent Collaborators

14 joint publications

Brian M Wolpin

13 joint publications

Andrew J Aguirre

13 joint publications

Harshabad Singh

11 joint publications

James M Cleary